New radiation approach aims to cut treatment time for rare sarcoma
NCT ID NCT06812052
First seen Oct 31, 2025 · Last updated May 15, 2026 · Updated 26 times
Summary
This early-phase trial tests a shorter, more intense radiation schedule for people with retroperitoneal sarcoma, a rare cancer in the abdomen. The main goal is to see if this approach is safe by tracking side effects like nausea and diarrhea within 30 days. Only 6 participants will be enrolled to help guide future research.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RETROPERITONEAL SARCOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Brigham and Women's Hospital / Dana Farber Cancer Institute
RECRUITINGBoston, Massachusetts, 02446, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.